- Home
- GALT vs RVPHW Comparison
GALT vs RVPHW Comparison
Compare GALT & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- RVPHW
- Stock Information
- Founded
- GALT 2000
- RVPHW N/A
- Country
- GALT United States
- RVPHW United States
- Employees
- GALT N/A
- RVPHW 15
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- RVPHW Health Care
- Exchange
- GALT Nasdaq
- RVPHW Nasdaq
- Market Cap
- GALT 147.8M
- RVPHW N/A
- IPO Year
- GALT N/A
- RVPHW 2018
- Fundamental
- Price
- GALT $1.04
- RVPHW $0.14
- Analyst Decision
- GALT Strong Buy
- RVPHW
- Analyst Count
- GALT 1
- RVPHW 0
- Target Price
- GALT $11.00
- RVPHW N/A
- AVG Volume (30 Days)
- GALT 1.1M
- RVPHW N/A
- Earning Date
- GALT 11-13-2024
- RVPHW N/A
- Dividend Yield
- GALT N/A
- RVPHW N/A
- EPS Growth
- GALT N/A
- RVPHW N/A
- EPS
- GALT N/A
- RVPHW N/A
- Revenue
- GALT N/A
- RVPHW N/A
- Revenue This Year
- GALT N/A
- RVPHW N/A
- Revenue Next Year
- GALT N/A
- RVPHW N/A
- P/E Ratio
- GALT N/A
- RVPHW N/A
- Revenue Growth
- GALT N/A
- RVPHW N/A
- 52 Week Low
- GALT $0.73
- RVPHW N/A
- 52 Week High
- GALT $4.27
- RVPHW N/A
- Technical
- Relative Strength Index (RSI)
- GALT 20.80
- RVPHW N/A
- Support Level
- GALT $1.80
- RVPHW N/A
- Resistance Level
- GALT $2.36
- RVPHW N/A
- Average True Range (ATR)
- GALT 0.27
- RVPHW 0.00
- MACD
- GALT -0.08
- RVPHW 0.00
- Stochastic Oscillator
- GALT 15.07
- RVPHW 0.00
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.